摘要
目的:回顾性分析重组人血管内皮抑素(恩度,endostar)联合XELOX(希罗达联合奥沙利铂)方案化疗治疗进展期胃癌的临床疗效和不良反应。方法:于2006年5月至2007年5月,收集60例进展期胃癌患者,随机分为治疗组和对照组各30例。治疗组采用恩度15mg+生理盐水500ml,静脉滴注3小时,第1～14天,联合化疗为奥沙利铂130mg/m2,静脉滴注3小时,第1天,希罗达800-1000mg/m2,口服,第1～14天,每3周重复。对照组除恩度外,化疗同治疗组。同时评价疗效和不良反应。结果:治疗组和对照组的有效率分别为63.3%和36.6%(P<0.05),疾病控制率分别为86.6%和70.0%(P>0.05);生存方面,治疗组和对照组的1、2年生存率分别为90.4%、51.0%和69.3%、19.8%,经检验P值均小于0.05;不良反应无差别。结论:恩度联合XELOX方案化疗治疗进展期胃癌疗效确切,安全,方便,并且优于对照组;不良反应可以耐受。
Objective： To analyze the clinical efficacy and toxicity of rh-endostatin （endostar） combined with XELOX for treatment of advanced gastric cancer. Methods： From May 2006 to May 2007, 60 patients were enrolled in the study and were randomly divided into the treatment group （30 cases） and the control group （30 cases）. In the treatment group, patients received endostar 15mg＋NS 500mL, iv.gtt. 3 hours daily, d1-d14; L-ohp 130mg/m^2＋5% glucose 500mL iv.gtt, 3 hours dl, Xeloda 800-1000mg/m^2, p.o. twice d1-d14. The treatment was repeated every three weeks. In the control group, patients received the same treatment without endostar. Results： The response rate was 63.3% in the treatment group and 36.6% in the control group （P〈0.05）. The disease control rate was 86.6% in the treatment group and 70.0% in the control group （P〉0.05）. The 1- and 2-year survival rates were 90.4% and 51.0% in the treatment group and 69.3% and 19.8% in the control group, respectively （P〈0.05）. No significant difference was found in adverse effects between the two groups. Conclusion： Endostar combined with XELOX is a safe and effective treatment for advanced gastric cancer with tolerable adverse effects.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2009年第17期976-979,共4页
Chinese Journal of Clinical Oncology
